Latest ACR News
-
Read ArticleDr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
Jonathan Hausmann MD hausmannMD
4 years 6 months ago
Haploinsufficiency 20 (HA20) is a newly-described autoinflammatory disease caused by mutations in TNFAIP3, encoding the NF-kB regulatory protein A20.
#ACR19 @RheumNow
Janet Pope Janetbirdope
4 years 6 months ago
Gout guidelines Allopurinol over febuxostat, dose low &slowly increase, T2T for serum Uric acid. Only Febuxostat if allopurinol failure/hypersensitivity. Only if failing with flares &tophi use peguricase. flares: colchicine steroids or NSAIDs #ACR @RheumNow https://t.co/ec6bOs5Hxo
Gout Study Group GoutGroup
4 years 6 months ago
2020 DRAFT ACR #gout Clinical Guidelines strongly recommend setting a serum urate goal and an active strategy to reach that goal @RheumNow https://t.co/8A6iTJgRPJ
Myosin Regulation May Contribute to Anti-TNF Therapy Response: Dr. Elaine Husni
Dr. Husni highlights abstract #1769 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew
Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Studies on the Changing Face of RA: Dr. Janet Pope
Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: Rheumatoid Arthritis
Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more.
Drug Levels Associated with Lupus Flares: Dr. Janet Pope:
Dr. Pope discusses abstract #2567 Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates presented at the 2019 ACR/ARP annual meeting in Atlanta.
Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush
Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. Rachel Tate uptoTate
4 years 6 months ago
Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #ACR19 @RheumNow abs#2878 https://t.co/OmlhZfGdJi
Jonathan Hausmann MD hausmannMD
4 years 6 months ago
What unmet needs are found by young rheumatologists in Latin America? —>The opportunity to conduct research, especially money and time. Dr. Toro Gutierrez #ACR19 @RheumNow
Dr. Rachel Tate uptoTate
4 years 6 months ago
30-day rehospitalization after primary TKA or THA more likely in RA pts vs OA pts. All-type infections, AKI, and mechanical complications most common. https://t.co/iwPn9lCLrT #ACR19 @RheumNow abs#2872 https://t.co/hRUCXOysme
Dr. John Cush RheumNow
4 years 6 months ago
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Horizon Therapeutics. All content chosen by RheumNow and its faculty.
Dr. Rachel Tate uptoTate
4 years 6 months ago
Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/uHvkFJn5z7 #ACR19 @RheumNow abs#2881 https://t.co/2EfzmyxY4M
Cassandra Calabrese CCalabreseDO
4 years 6 months ago
Rilonacept may have a role in Tx of steroid-refractory recurrent idiopathic pericarditis abstr#2905 #ACR19 #cleclinicrheum @RheumNow @CleClinicMD
Poster Hall